Multidisciplinary and integrated solutions to influence and guide a drug discovery program from inception to IND filing
With comprehensive and expansive capabilities in biology, GVK BIO offers high-quality, cost-effective solutions across the pharma and biotech value chain. Biological assessment of New Molecular Entities (NMEs) plays a crucial role in ascertaining structure activity relationships, potency, selectivity, druggability, in vitro and in vivo efficacy evaluations.
From hit identification to clinical candidate selection:
A Highly Reproducible In Vivo Model for Bleomycin-Induced Lung Fibrosis in Mice to Evaluate Drugs for the Treatment of Idiopathic Pulmonary Fibrosis
Download the Whitepaper